Latest news with #JasonChan
South China Morning Post
3 days ago
- Entertainment
- South China Morning Post
Golden Harvest closes its 4 remaining cinemas amid industry upheaval in Hong Kong
Golden Harvest shut down all four of its remaining cinemas in Hong Kong on Sunday, including one that will not be leased to a new operator, leaving residents disappointed by the loss of another venue. GH Galaxy in Shau Kei Wan ceased operations, while Golden Harvest's other three cinemas, Sky at Olympian City, StagE in Tuen Mun and GH in Tai Po will all be leased to a new operator from Monday. On its final day, GH Galaxy offered six showings across its two screens. By 5.30pm, the only sold-out showing was Behind the Shadows, a new release from June 12, with many empty seats in other screenings, particularly in the front rows. 'To be honest, I am not so surprised to hear about the closure,' Jason Chan, an architect in his thirties who lives a 10-minute walk away, told the Post at the cinema. 'First, there are fewer and fewer screenings, and then there is no staff working here – only self-service machines now. I can feel it is dying slowly.' Chan expressed his regret but hoped a new operator might take over in the future. Another resident, who identified himself as Danny L, said he would miss the 'human touch' of Golden Harvest cinemas. He noted that the chain often hosted events where film-goers could meet actors and actresses, while he also appreciated the friendly staff.
The Sun
5 days ago
- Health
- The Sun
Tanoto Foundation Backs Landmark Research to Unlock the Code of Asian Prevalent Diseases
SINGAPORE - Media OutReach Newswire - 27 June 2025 - Tanoto Foundation today announced the funding of two transformative, Singapore-based medical research projects focused on diseases that disproportionately affect Asian populations: prevalent and aggressive cancers, and young-onset Type 2 diabetes. The multi-year initiatives aim to generate data-driven insights that can accelerate diagnosis, improve patient outcomes, and guide public health policy. Despite global strides in medicine, Asia continues to face rising rates of cancer and diabetes – diseases that are biologically and clinically distinct in Asian populations but remain under-researched due to a lack of region-specific data. The two research projects, from National Cancer Centre Singapore and Singapore General Hospital, will focus on filling these gaps through deep genomic studies and innovative risk-prediction models. Imelda Tanoto, Member of the Board of Trustees, Tanoto Foundation said: 'Singapore is well-positioned to lead in medical science. It has strong research institutions and a population that reflects the diversity of Asia. By supporting researchers here who are focused on health issues that affect Asians, we hope to help drive discoveries that make a real difference to people's lives — both in Singapore and across the region.' Tackling Asian-Prevalent Cancers Led by Dr Jason Chan, Medical Oncologist, National Cancer Centre Singapore, the research will investigate four types of cancers with high prevalence and poor outcomes in Asia: • Breast Cancer in Asian Women, marked by earlier onset and biological differences compared to Western populations • T/NK-Cell Lymphomas, an aggressive blood cancer dominant in East Asians with limited treatment options • Bile Duct Cancer (Cholangiocarcinoma), increasingly linked to environmental exposures specific to Asia • Rare Asian Cancers, collectively neglected but accounting for up to 25% of all cases in the region These cancers are devastating but remain poorly understood because most research has focused on Western populations,' said Dr Chan. 'By decoding their molecular and genomic landscapes in Asian patients, we want to uncover new diagnostic and therapeutic opportunities to benefit patients.' A key feature of the project is its open-access commitment: anonymised data will be freely available to the broader research community to accelerate further discovery and collaboration. Unmasking Diabetes Risk in Young Singaporeans The second research project, led by Dr Daphne Gardner, Endocrinologist, Singapore General Hospital, will address the rising incidence of Type 2 diabetes in young adults, particularly prevalent in Singapore, where 1 in 5 young adults have prediabetes or diabetes, despite being of normal weight. Unlike traditional assessments that rely heavily on BMI and family history, this project will develop a next-generation risk prediction tool by incorporating non-traditional indicators such as body fat distribution, continuous glucose monitoring, and health-seeking behaviour. 'Many young Asians with diabetes don't fit the usual risk profile. They're lean, may not have hypertension, and are therefore often overlooked by current screening models,' said Dr Gardner. 'We want to change that by identifying new risk signals and developing tools that are tailored to Singapore's population and the region.' Findings from the study aim to inform national diabetes screening guidelines and lead to earlier interventions that can curb long-term complications. Singapore as a Hub for Medical Research Advancement In addition to previously supported research projects, these two initiatives reflect a growing recognition of Singapore's role in advancing precision medicine for Asian populations, driven by strong clinical infrastructure, genomic capabilities, and public-private partnerships. Imelda Tanoto added: 'We believe precision health can change how we treat and prevent diseases. We're supporting researchers who are not only breaking new ground, but also making sure their work reaches people and communities across Asia. This is something deeply personal to us — it's about improving lives in a way that's inclusive, meaningful, and lasting.' This announcement marks a key milestone in Tanoto Foundation's continuing effort to improve the quality of healthcare and health standards, leading to longer and better healthspans. Hashtag: #TanotoFoundation The issuer is solely responsible for the content of this announcement.
Arabian Post
6 days ago
- Health
- Arabian Post
Tanoto Foundation Backs Landmark Research to Unlock the Code of Asian Prevalent Diseases
Understanding Asian Cancers and Diabetes Through an Asian Lens SINGAPORE – Media OutReach Newswire – 27 June 2025 – Tanoto Foundation today announced the funding of two transformative, Singapore-based medical research projects focused on diseases that disproportionately affect Asian populations: prevalent and aggressive cancers, and young-onset Type 2 diabetes. The multi-year initiatives aim to generate data-driven insights that can accelerate diagnosis, improve patient outcomes, and guide public health policy. NCCS and SGH secure research funding from Tanoto Foundation for projects tackling Asian-prevalent cancers and young-onset diabetes to drive breakthroughs in regional health Despite global strides in medicine, Asia continues to face rising rates of cancer and diabetes – diseases that are biologically and clinically distinct in Asian populations but remain under-researched due to a lack of region-specific data. The two research projects, from National Cancer Centre Singapore and Singapore General Hospital, will focus on filling these gaps through deep genomic studies and innovative risk-prediction models. ADVERTISEMENT Imelda Tanoto, Member of the Board of Trustees, Tanoto Foundation said: 'Singapore is well-positioned to lead in medical science. It has strong research institutions and a population that reflects the diversity of Asia. By supporting researchers here who are focused on health issues that affect Asians, we hope to help drive discoveries that make a real difference to people's lives — both in Singapore and across the region.' Tackling Asian-Prevalent Cancers Led by Dr Jason Chan, Medical Oncologist, National Cancer Centre Singapore, the research will investigate four types of cancers with high prevalence and poor outcomes in Asia: Breast Cancer in Asian Women, marked by earlier onset and biological differences compared to Western populations T/NK-Cell Lymphomas, an aggressive blood cancer dominant in East Asians with limited treatment options Bile Duct Cancer (Cholangiocarcinoma), increasingly linked to environmental exposures specific to Asia Rare Asian Cancers, collectively neglected but accounting for up to 25% of all cases in the region These cancers are devastating but remain poorly understood because most research has focused on Western populations,' said Dr Chan. 'By decoding their molecular and genomic landscapes in Asian patients, we want to uncover new diagnostic and therapeutic opportunities to benefit patients.' A key feature of the project is its open-access commitment: anonymised data will be freely available to the broader research community to accelerate further discovery and collaboration. Unmasking Diabetes Risk in Young Singaporeans The second research project, led by Dr Daphne Gardner, Endocrinologist, Singapore General Hospital, will address the rising incidence of Type 2 diabetes in young adults, particularly prevalent in Singapore, where 1 in 5 young adults have prediabetes or diabetes, despite being of normal weight. ADVERTISEMENT Unlike traditional assessments that rely heavily on BMI and family history, this project will develop a next-generation risk prediction tool by incorporating non-traditional indicators such as body fat distribution, continuous glucose monitoring, and health-seeking behaviour. 'Many young Asians with diabetes don't fit the usual risk profile. They're lean, active, and often overlooked by current screening models,' said Dr Gardner. 'We want to change that by identifying new risk signals and developing tools that are tailored to Singapore's population and beyond.' Findings from the study aim to inform national diabetes screening guidelines and lead to earlier interventions that can curb long-term complications. Singapore as a Hub for Medical Research Advancement In addition to previously supported research projects, these two initiatives reflect a growing recognition of Singapore's role in advancing precision medicine for Asian populations, driven by strong clinical infrastructure, genomic capabilities, and public-private partnerships. Imelda Tanoto added: 'We believe precision health can change how we treat and prevent diseases. We're supporting researchers who are not only breaking new ground, but also making sure their work reaches people and communities across Asia. This is something deeply personal to us — it's about improving lives in a way that's inclusive, meaningful, and lasting.' This announcement marks a key milestone in Tanoto Foundation's continuing effort to improve the quality of healthcare and health standards, leading to longer and better healthspans. Hashtag: #TanotoFoundation The issuer is solely responsible for the content of this announcement. About Tanoto Foundation At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realize his or her full potential. To do so, we catalyse systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes. More information is available at
Business Recorder
21-06-2025
- Business
- Business Recorder
HK stocks log worst week since April
SHANGHAI: Hong Kong stocks rebounded on Friday but still logged their steepest weekly decline since April, as the lack of new stimulus measures this week weighed on investor sentiment amid broader global tensions surrounding the Iran-Israel conflict. The Hong Kong stock market had witnessed a steady recovery over recent weeks, rebounding from losses triggered by reciprocal tariffs imposed by US President Donald Trump. The benchmark Hang Seng Index has advanced 17% year-to-date. 'The Lujiazui forum this week offered no new measures to boost the capital market, which was a potential letdown for some investors,' said Jason Chan, senior investment strategist at Bank of East Asia. The two-day gathering of top financial regulators and market participants at the annual Lujiazui Forum wrapped up on Thursday, delivering few surprises for market participants. Sentiment is expected to remain weak, with the persistent risk of an escalation in Middle East tensions continuing to cast a shadow over markets, Chan said. 'The market could stay range-bound in the short term.' China kept its benchmark lending rates unchanged on Friday, as expected, after rolling out sweeping monetary easing measures last month to support the economy. China's blue-chip CSI300 Index closed 0.1% higher, while the Shanghai Composite Index lost 0.1%. Hong Kong benchmark Hang Seng was up 1.3%. For the week, the Hang Seng Index was down 1.5%, the biggest drop since the week of April 7, while the CSI300 Index was down 0.5%. Hong Kong's pullback was also exacerbated by fading interest from mainland investors. Their purchases via the Stock Connect scheme have slowed sharply in recent weeks, with net buying this week amounting to just 16 billion yuan ($2.23 billion) — only 20% of the peak recorded in April. The CSI Liquor Index rose 2.2%, leading gains onshore, after the index lost 12% this year on weak consumer demand and a government ban on civil servants dining out. Amid uncertainties related to China-US trade friction, onshore share valuations may be range-bound at low levels near term, UBS strategist Lei Meng said in a note. 'We expect limited downside, and potential upside catalysts mainly from stronger policy easing, the continual entry of medium or long-term funds and structural reforms,' Meng said. Shares of 'Blind Box' toymaker Pop Mart dropped nearly 4% after state media outlet People's Daily called for stricter regulation of the blind box industry, citing expert views. The stock has fallen 13% this week, but soared 165% this year.
RTHK
20-06-2025
- Business
- RTHK
Hang Seng Index ends bad week with a rebound
Hang Seng Index ends bad week with a rebound The Hang Seng Index ended the day with gains of 292.74 points, or 1.26 percent, at 23,530.48. File photo: RTHK Hong Kong stocks rebounded on Friday but still logged their steepest weekly decline since April, as the lack of new stimulus measures this week weighed on investor sentiment amid broader global tensions surrounding the Iran-Israel conflict. The benchmark Hang Seng Index ended the day with gains of 292.74 points, or 1.26 percent, at 23,530.48. The Hang Seng China Enterprises Index rose 1.38 percent to end at 8,527.07 while the Hang Seng Tech Index rose 0.88 percent to end at 5,133.14. Across the border, the benchmark Shanghai Composite Index ended down 0.07 percent at 3,359.90 while the Shenzhen Component Index closed 0.47 percent lower at 10,005.03. The ChiNext Index, tracking China's Nasdaq-style board of growth enterprises, lost 0.84 percent to close at 2,009.89. The Hong Kong stock market had witnessed a steady recovery over recent weeks, rebounding from losses triggered by reciprocal tariffs imposed by US President Donald Trump. The benchmark Hang Seng Index has advanced 17 percent in the year to date. "The Lujiazui forum this week offered no new measures to boost the capital market, which was a potential letdown for some investors," said Jason Chan, senior investment strategist at Bank of East Asia. The two-day gathering of top financial regulators and market participants at the annual Lujiazui Forum wrapped up on Thursday, delivering few surprises for market participants. Sentiment is expected to remain weak, with the persistent risk of an escalation in Middle East tensions continuing to cast a shadow over markets, Chan said. "The market could stay range-bound in the short term." China kept its benchmark lending rates unchanged on Friday, as expected, after rolling out sweeping monetary easing measures last month to support the economy. For the week, the Hang Seng Index was down 1.5 percent, the biggest drop since the week of April 7, while the CSI300 Index was down 0.5 percent. (Reuters/Xinhua)
